Navinci develops technologies that enable researchers to study proteins and their functional interactions directly in cells and tissues. The company’s in situ Proximity Ligation Assay (isPLA) technology enables highly sensitive detection of proteins, protein interactions and post-translational modifications. This helps researchers better understand disease mechanisms, drug mode of action and identify which patients are most likely to respond to a treatment.